Sebastian Havervall, Ulrika Marking, Nina Greilert-Norin, Max Gordon, Henry Ng, Wanda Christ, Mia Phillipson, Peter Nilsson, Sophia Hober, Kim Blom, Jonas Klingstr?m, Sara Mangsbo, Mikael ?berg, Charlotte Th?lin
{"title":"SARS-CoV-2感染对疫苗诱导的免疫反应的影响","authors":"Sebastian Havervall, Ulrika Marking, Nina Greilert-Norin, Max Gordon, Henry Ng, Wanda Christ, Mia Phillipson, Peter Nilsson, Sophia Hober, Kim Blom, Jonas Klingstr?m, Sara Mangsbo, Mikael ?berg, Charlotte Th?lin","doi":"10.1002/cti2.1388","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To determine the long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using longitudinally collected blood samples from the COMMUNITY study, we determined binding (WHO BAU mL<sup>−1</sup>) and neutralising antibody titres against ten SARS-CoV-2 variants over 7 months following BNT162b2 in SARS-CoV-2-recovered (<i>n</i> = 118) and SARS-CoV-2-naïve (<i>n</i> = 289) healthcare workers with confirmed prior SARS-CoV-2 infection. A smaller group with (<i>n</i> = 47) and without (<i>n</i> = 60) confirmed prior SARS-CoV-2 infection receiving ChAdOx1 nCoV-19 was followed for 3 months. SARS-CoV-2-specific memory T-cell responses were investigated in a subset of SARS-CoV-2-naïve and SARS-CoV-2-recovered vaccinees.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Vaccination with both vaccine platforms resulted in substantially enhanced T-cell responses, anti-spike IgG responses and neutralising antibodies effective against ten SARS-CoV-2 variants in SARS-CoV-2-recovered participants as compared to SARS-CoV-2-naïve participants. The enhanced immune responses sustained over 7 months following vaccination.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These findings imply that prior SARS-CoV-2 infection should be taken into consideration when planning booster doses and design of current and future COVID-19 vaccine programmes.</p>\n </section>\n </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"11 4","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2022-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1388","citationCount":"20","resultStr":"{\"title\":\"Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time\",\"authors\":\"Sebastian Havervall, Ulrika Marking, Nina Greilert-Norin, Max Gordon, Henry Ng, Wanda Christ, Mia Phillipson, Peter Nilsson, Sophia Hober, Kim Blom, Jonas Klingstr?m, Sara Mangsbo, Mikael ?berg, Charlotte Th?lin\",\"doi\":\"10.1002/cti2.1388\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To determine the long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Using longitudinally collected blood samples from the COMMUNITY study, we determined binding (WHO BAU mL<sup>−1</sup>) and neutralising antibody titres against ten SARS-CoV-2 variants over 7 months following BNT162b2 in SARS-CoV-2-recovered (<i>n</i> = 118) and SARS-CoV-2-naïve (<i>n</i> = 289) healthcare workers with confirmed prior SARS-CoV-2 infection. A smaller group with (<i>n</i> = 47) and without (<i>n</i> = 60) confirmed prior SARS-CoV-2 infection receiving ChAdOx1 nCoV-19 was followed for 3 months. SARS-CoV-2-specific memory T-cell responses were investigated in a subset of SARS-CoV-2-naïve and SARS-CoV-2-recovered vaccinees.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Vaccination with both vaccine platforms resulted in substantially enhanced T-cell responses, anti-spike IgG responses and neutralising antibodies effective against ten SARS-CoV-2 variants in SARS-CoV-2-recovered participants as compared to SARS-CoV-2-naïve participants. The enhanced immune responses sustained over 7 months following vaccination.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>These findings imply that prior SARS-CoV-2 infection should be taken into consideration when planning booster doses and design of current and future COVID-19 vaccine programmes.</p>\\n </section>\\n </div>\",\"PeriodicalId\":152,\"journal\":{\"name\":\"Clinical & Translational Immunology\",\"volume\":\"11 4\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2022-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1388\",\"citationCount\":\"20\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1388\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1388","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time
Objective
To determine the long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination.
Methods
Using longitudinally collected blood samples from the COMMUNITY study, we determined binding (WHO BAU mL−1) and neutralising antibody titres against ten SARS-CoV-2 variants over 7 months following BNT162b2 in SARS-CoV-2-recovered (n = 118) and SARS-CoV-2-naïve (n = 289) healthcare workers with confirmed prior SARS-CoV-2 infection. A smaller group with (n = 47) and without (n = 60) confirmed prior SARS-CoV-2 infection receiving ChAdOx1 nCoV-19 was followed for 3 months. SARS-CoV-2-specific memory T-cell responses were investigated in a subset of SARS-CoV-2-naïve and SARS-CoV-2-recovered vaccinees.
Results
Vaccination with both vaccine platforms resulted in substantially enhanced T-cell responses, anti-spike IgG responses and neutralising antibodies effective against ten SARS-CoV-2 variants in SARS-CoV-2-recovered participants as compared to SARS-CoV-2-naïve participants. The enhanced immune responses sustained over 7 months following vaccination.
Conclusion
These findings imply that prior SARS-CoV-2 infection should be taken into consideration when planning booster doses and design of current and future COVID-19 vaccine programmes.
期刊介绍：
Clinical & Translational Immunology is an open access, fully peer-reviewed journal devoted to publishing cutting-edge advances in biomedical research for scientists and physicians. The Journal covers fields including cancer biology, cardiovascular research, gene therapy, immunology, vaccine development and disease pathogenesis and therapy at the earliest phases of investigation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
